Compared to chemical agents such as tyrosine kinase inhibitors which are not tumor specific and bear the risk of severe side effects [28], P9 has potential for high selectivity because it targets interactions between bFGF and its receptors, and may be safer to use from a clinical point of view. The gene discussed is FGF2; the disease is neoplasm.